CANNAQIX

Creso Pharma brings marketing and sales of cannaQIX® in-house

Finfeed Archived Feb 08, 2021

Creso Pharma (ASX: CPH) is taking over the marketing and sales strategy for cannaQIX®, effectively improving profit margins.

Creso Pharma leads the way in burgeoning cannabis market

Finfeed Archived Jan 29, 2021

Creso Pharma looks set to start the year on a strong note after an impressive performance in the December quarter of 2020

Creso Pharma delivers second shipment of cannaQIX® adding $320K to growing revenue base

Finfeed Archived Jan 12, 2021

Creso Pharma has delivered a second shipment of cannaQIX® products to Lupin International subsidiary, Pharma Dynamics

Creso Pharma to benefit from OTC cannabis sales in Australia

Finfeed Archived Sep 10, 2020

The TGA has recommended that CBD products be down-scheduled to schedule 3 medicines in Australia, allowing OTC sales, which should benefit Creso Pharma (ASX: CPH).

Cannaqix

Creso Pharma brings marketing and sales of cannaQIX® in-house

Creso Pharma leads the way in burgeoning cannabis market

Creso Pharma delivers second shipment of cannaQIX® adding $320K to growing revenue base

Creso Pharma to benefit from OTC cannabis sales in Australia